Ankit Kansagra, Associate Vice President Oncology Integration and Community Alliance at Tampa General Hospital, shared on X:
”Phase 3 readout from MonumenTAL-6 – and the effect size here is hard to ignore.
MonumenTAL-6 / Phase 3 / relapsed/refractory myeloma, 1–4 prior lines (anti-CD38– and len–exposed) – patient population with true unmet need in clinic. Two off-the-shelf bispecifics, together, moved earlier in the disease course: TECVAYLI (teclistamab, anti-BCMA) + TALVEY (talquetamab, anti-GPRC5D) PFS HR 0.11 → 89% reduction in risk of progression or death.
OS HR 0.38 → 62% reduction in risk of death vs investigator’s choice (EPd / PVd) The TALVEY + pomalidomide arm also beat standard of care (PFS HR 0.27).
An HR of 0.11 in a randomized Phase 3 isn’t a number we see often. The real story is the dual BCMA/GPRC5D doublet truly emerging as SOC in early relapse Grateful to the entire MonumenTAL-6 team. This was a true group effort, and I’m proud to have an opportunity to help advance this amazing therapy for our patients.
Check out our ASH 2024 Abstract of Trial in progress for study design.”
Title: Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody
Authors:Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez-Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara J. Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau
Other articles about myeloma on OncoDaily.